Published on | by redblob2
The New Psoriasis Bro, “Brodalumab”
Unless you’ve been locked inside a cupboard over the past few weeks, you should have heard the news by now. There’s a new biologic on the block, and he goes by the name of brodalumab. He’s a bro that’s got your back. Your flaky back.
Made by Amgen and AstraZeneca, brodalumab is raising eyebrows because its just passed a phase III trial with flying colours. According to Bloomberg, it works in “a different manner than existing drugs” by fastening itself onto the interleukin 17 receptor (also known as IL-17). Essentially, this cell is a tiny protein that promotes inflammation, and has been linked to immune disorders from rheumatoid arthritis to psoriasis.
In the latest trial, the drug performed pretty well. Out of 661 patients, 84% receiving a high dose and 60% receiving the lower dose saw their psoriasis improve by 75%. From what I’ve read, the drug was delivered via subcutaneous injections once every fortnight. Only 2.7% of patients given the placebo saw similar results, which is saying something.
Brodalumab is going to be a direct competitor to Stelara and Enbrel. Personally, I am strongly against the use of immunosuppressants in most cases, unless the psoriasis is having a humongous impact on quality of life.
But whether I’m against it or not, the use of biologics is going to keep growing regardless. Indeed, a new report has come out saying that the “systemic psoriasis market” is going to grow from USD 5 billion in 2013 to USD 10.4 billion in 2020. That’s a damn load of injections!